Cancer Treatment Gets Personal

New class of drugs show off at ASCO

What happens when a preliminary study that was not designed for drug approval ends up showing dramatic results?  [MORE]

How do we improve clinical trial participation?

Physicians, researchers, and industry officials gathered to discuss the reasons for slow trial accrual and ways to improve it. [MORE]

When cancer breakthroughs hit home

For someone who may have had triple-negative breast cancer, the news on PARP inhibitors was a small personal victory.

[MORE]

Study shows how to prevent rash from EGFR Inhibitors

Doctors now know how to prevent the skin rash that develops in up to 90 percent of patients receiving these drugs. [MORE]

Highlights From the 2009 ASCO Annual Meeting

PARP Inhibitors Successful Against Hard-to-Treat Breast Cancers

A new class of drugs called PARP inhibitors is getting some serious attention after a study in metastatic triple-negative breast cancer patients found that the agent BSI-201 significantly improved survival. [MORE]

Zactima Delays Advanced Lung Cancer Growth

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed. [MORE]

Antidepressants Reduce the Effectiveness of Tamoxifen

Taking tamoxifen with certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence. [MORE]

Herceptin Improves Survival in Gastric Cancer

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study. [MORE]

Therapeutic Vaccine Delays Lymphoma Recurrence

Researchers of a follicular lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay recurrences. [MORE]

CA-125 Monitoring Not Helpful for Ovarian Cancer Survivors

Results from an international study challenge the current practice of screening for ovarian cancer relapse. [MORE]

Trial Confirms Benefit of Targeted Combination in Lung Cancer

A large phase III study, which examined whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer, reached its primary goal. [MORE]

Avastin Successful With Various Chemotherapies

in Breast Cancer

Adding Avastin to standard therapy delayed progression of advanced HER2-negative breast cancer in women without prior treatment. [MORE]

New Test Predicts Colon Cancer Recurrence

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence. [MORE]

Avastin Falls Short in Early-Stage Colon Cancer

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence. [MORE]

Become a fan of CURE on Facebook

Follow CURE on Twitter

Submit your personal experience essays to editor@curetoday.com

To purchase a back issue, click here.

Sign up for our e-mail newsletters, which you can now personalize by tumor type, survivorship, or caregiver status.

This e-mail was sent to you because you have provided your e-mail address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add curextra@curetoday.com to your address book or safe sender list to ensure this e-mail is delivered to your inbox.

© 2009 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic, or treatment advice.